Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's drug

This page shows the latest Alzheimer's drug news and features for those working in and with pharma, biotech and healthcare.

Biogen’s highly-anticipated Alzheimers drug wins FDA fast-track

Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track

Drug could become first treatment to reduce clinical decline in Alzheimer's. ... Biogen has picked up a US Food and Drug Administration (FDA) fast-track review for its experimental Alzheimer’s disease treatment aducanumab.

Latest news

More from news
Approximately 1 fully matching, plus 123 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimers: the search for a cure

    Tau is emerging as a target for drug development in Alzheimer’s, as well as other disorders like frontotemporal dementia. ... Organisations including the Alzheimer’s Drug Discovery Foundation (ADDF) think combinations of molecules with these

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimers ahead of a cure

    Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate. ... It was just another in a string of late-stage

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimers disease R&D?

    This evidence has spurred research and led. organisations including the Alzheimer’s Drug Discovery Foundation and AC Immune to conclude that combination therapies may be needed to tackle such a complex ... Read more: Brain power: fresh approaches to

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimers drug discovery

    Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc. ... Corporate acquisition. 400.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Bone Therapeutics looks to Pfizer for clinical head Bone Therapeutics looks to Pfizer for clinical head

    He has spent a majority of his career at Pfizer, where he held a number of senior roles including medical director for Pfizer Switzerland, European team leader for the Alzheimer's ... disease drug Aricept and medical team leader for its anti-inflammatory

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics